Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001103021-20-000010
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-01-17 16:06:29
Reporting Period:
2020-01-15
Accepted Time:
2020-01-17 16:06:29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1103021 Biodelivery Sciences International Inc BDSI Pharmaceutical Preparations (2834) 352089858
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1720772 Theresa Mary Coelho C/o Biodelivery Sciences Intl, Inc.
4131 Parklake Ave. Suite 225
Raleigh NC 27612
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-01-15 18,333 $0.00 18,333 No 4 M Direct
Common Stock Acquisiton 2020-01-15 35,703 $3.73 54,036 No 4 M Direct
Common Stock Disposition 2020-01-16 42,018 $5.98 12,018 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2020-01-15 18,333 $0.00 18,333 $0.00
Common Stock Stock Options (right to buy) Disposition 2020-01-15 35,703 $3.73 35,703 $3.73
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
36,667 2020-01-15 2022-01-17 No 4 M Direct
71,406 2020-01-15 2029-01-17 No 4 M Direct
Footnotes
  1. The shares of Common Stock were automatically exercised and sold under a pre-planned 10b5-1 trading plan.
  2. On January 16, 2020, the Reporting Person sold an aggregate of 42,018 shares of the Issuer's Common Stock at a weighted average price of $5.98 per share. The highest sale price for the Common Stock was $6.00 per share and the lowest sale price was $5.89 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
  3. The shares of common stock were acquired by the Reporting Person as a result of the vesting of 18,333 Restricted Stock Units ("RSUs") granted to the Reporting Person on January 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. The remainder of the RSUs under this grant vest in equal portions on: (i) January 15, 2021; and (ii) January 15, 2022.
  4. The shares of common stock were acquired by the Reporting Person as a result of the exercise of stock options granted to the Reporting Person on January 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. The remainder of the stock options under this grant vest in equal portions on: (i) January 15, 2021; and (ii) January 15, 2022.